Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

被引：0
|
作者：
Rosen, N. L. [1 ]
Mathew, P. G. [2 ]
Buchanan, A. S. [3 ]
Baygani, S. [3 ]
Hochstetler, H. [4 ]
Khanna, R. [3 ]
机构：
[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Sharon, MA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [11] Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
    Lipton, Richard B.
    Lombard, Louise
    Ruff, Dustin D.
    Krege, John H.
    Loo, Li Shen
    Buchanan, Andrew
    Melby, Thomas E.
    Buse, Dawn C.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [12] Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
    Richard B. Lipton
    Louise Lombard
    Dustin D. Ruff
    John H. Krege
    Li Shen Loo
    Andrew Buchanan
    Thomas E. Melby
    Dawn C. Buse
    [J]. The Journal of Headache and Pain, 2020, 21
  • [13] Rapid Responders to Frovatriptan in Acute Migraine Treatment: Results from a Long-Term, Open-Label Study
    Spierings, Egilius L. H.
    Keywood, Charlotte
    [J]. PAIN MEDICINE, 2009, 10 (04) : 633 - 638
  • [14] Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks
    de Dhaem, Olivia Begasse
    Takizawa, Tsubasa
    Dodick, David W.
    [J]. CEPHALALGIA, 2023, 43 (02)
  • [15] An open-label study to evaluate the long-term safety of zelrix™, a sumatriptan iontophoretic patch for the treatment of acute migraine
    Smith, T.
    Pierce, M.
    Griesser, J.
    Sebree, T.
    O'Neill, C.
    [J]. CEPHALALGIA, 2011, 31 (01) : 120 - 120
  • [16] Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
    Lipton, R. B.
    Berman, G.
    Kudrow, D.
    Mullin, K.
    Thiry, A. C.
    Lovegren, M.
    Coric, V
    Croop, R.
    [J]. HEADACHE, 2019, 59 : 175 - 175
  • [17] Long-Term, Open-Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents
    Berenson, Frank
    Vasconcellos, Elza
    Pakalnis, Ann
    Mao, Lian
    Biondi, David M.
    Armstrong, Robert B.
    [J]. HEADACHE, 2010, 50 (05): : 795 - 807
  • [18] Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
    Lipton, Richard B.
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    Coric, Vladimir
    Croop, Robert
    [J]. CEPHALALGIA, 2019, 39 : 189 - 189
  • [19] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [20] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    [J]. EPILEPSIA, 2005, 46 : 118 - 118
12345